1. Market Research
  2. > Biotechnology
  3. > Genetically Modified Organism Market Trends
Genome Editing/Genome Engineering Market by Technology, Application, End User - Global Forecast 2022

Genome Editing/Genome Engineering Market: Global Forecast

  • November 2017
  • 166 pages
  • ID: 5220258
In this report:
North America is expected to account for the largest share of ##.##% of the global genome editing market in 2017 and is projected to register the highest growth rate of ##.##% during the forecast period.
The CRISPR segment is expected to command the largest share of ##.##% of the global genome editing market in 2017 and is projected to register the highest CAGR of ##.##% during the forecast period.

Summary

Table of Contents

Search Inside

"The genome editing/genome engineering market is estimated to rise at a compound annual growth rate of 14.50 percent."

The overall genome editing market is anticipated to rise at a compound annual growth rate (CAGR) of 14.50 percent to reach to ~$6.3B by 2022. The main key factors propelling the increase of this market are growing government funding and increase in the number of genomics projects, high prevalence of infectious diseases and cancer, technological improvements, growing production of genetically modified crops, and increasing application areas of genomics.

"The CRISPR segment is anticipated to grow at the maximal rate during the outlook period."

By technology, the sector is divided into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine Base Editor, and Jump-In). The CRISPR segment is intended to grow at the maximal compound annual growth rate (CAGR) during the estimate period. The ease of use combined with the CRISPR technology is a significant advantage over ZFN and TALEN, especially in generating a important set of vectors to target numerous sites or even genome-wide libraries. Another potential advantage of CRISPR is its ability to multiplex, that is, to use multiple guide RNAs in parallel to target multiple sites simultaneously in the same cell. This makes it easier to mutate multiple genes at once or engineer precise deletions in a genomic area.

"The pharmaceutical and biotechnology companies segment is anticipated to be the quickest increasing end-user segment."

On the basis of end user, the sector is classified into pharmaceutical and biotechnology firms, academic & government research institutes, and contract research organizations. The pharmaceutical and biotechnology companies segment is forecasted to grow at the quickest rate during the outlook period. The rising prevalence of infectious diseases and cancer are driving research activities global; this is predicted to push the demand for genome editing in biotechnology & pharmaceutical companies.

"North America (NA) to lead the genome editing/genome engineering market and is expected to grow at the highest CAGR (Compound annual growth rate) during the estimate period."

The North American area is forecast to hold the biggest share of the overall market in 2017. This regional segment is also anticipated to grow at the highest compound annual growth rate (CAGR) during the outlook period. The big share and high increase rate of this area can be accredited to Elements such as the development of gene therapy in the USA, growing use of genetically modified crops, increasing prevalence of infectious diseases and cancer, and growing availability of research grants and funding.

Break of primary members taking part was as mentioned below:

• By Company category - Tier 1: 56.0 percent, Tier 2: 35.0 percent, and Tier 3: 9.0 percent

• By Description - C-suite: 27.0 percent, D-level: 15.0 percent, Others: 58.0 percent

• By Area - North America continent: 37.0 percent, Europe (EU): 23.0 percent, Asia Pacific (APAC): 25.0 percent, RoW: 15.0 percent

Thermo Fisher Scientific, Merck KGaA, and Horizon Discovery Group are some of the main players operating in the industry.

Segment Research

The industry report examines the sector and aims at estimating the market value and the future increase potential of this market established on several segments including technology, application, final user, and area. The study also comprises an detailed regulatory study for several areas across the world and competitive review of the top actors in this sector together with their company descriptions, product offerings, latest developments, and key industries strategies.

Reasons to Buy the Report

The analysis will increase established companies as well as new entrants/smaller companies to measure the pulse of the sector, which in turn would benefit them, collect a larger market share. Companies obtaining the market research could use any one or a combination of the below-mentioned strategies.

This industry report offers business insights on these pointers:

• Market Uptake: Exhaustive data on product types provided by the top actors in the overall genome editing/genome engineering market

• Product Enhancement/Innovative products: In-depth understanding on upcoming trends and launches of new product in the overall genome editing/genome engineering market

• Market Development: Highlighted information about the profitable emerging sectors by technology, application, end-user, and area

• industry diversification: Complete information about recent products or products consolidations, increasing geographies, recent evolutions, and market investments in the overall genome editing/genome engineering market

• opposing assessment: Detailed assessment of market shares, increase strategies, and products of leading actors in the overall market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
ASIA PACIFIC CRISPR MARKET FORECAST 2018-2026

ASIA PACIFIC CRISPR MARKET FORECAST 2018-2026

  • $ 1307
  • Industry report
  • January 2018
  • by Inkwood Research

KEY FINDINGSThe revenue generated by the Asia-Pacific CRISPR market is expected to catapult from $92 million in 2017 to $1725 million by 2026, at a CAGR of 38.86%. CRISPR majorly finds its applications ...

EUROPE CRISPR MARKET FORECAST 2018-2026

EUROPE CRISPR MARKET FORECAST 2018-2026

  • $ 1307
  • Industry report
  • January 2018
  • by Inkwood Research

KEY FINDINGSThe Europe CRISPR market is anticipated to evolve with 35.19% CAGR over the forecast period of 2018-2026. The revenue generated by this market is expected to increase from $120 million and ...

GLOBAL CRISPR MARKET FORECAST 2018-2026

GLOBAL CRISPR MARKET FORECAST 2018-2026

  • $ 2613
  • Industry report
  • January 2018
  • by Inkwood Research

KEY FINDINGSThe Global CRISPR market is expected to witness a boost of 36.53%CAGR over the forecast period of 2018-2026, raising a net total of $7955 million by the end of 2026. Factors like increasing ...

Drug Analysis: Rubraca $ 10000 January 2018


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on